Generic Name: binimetinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Pfizer

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Mektovi is a kinase inhibitor approved to treat inoperable or metastatic melanoma with BRAF V600E or V600K mutations in combination with Braftovi (encorafenib).

General Info

Mektovi is a targeted therapy that interferes with the activity of MEK (mitogen-activated extracellular signal-regulated kinase) proteins that play a role in cell growth. It is more effective when combined with the BRAF inhibitor Braftovi. Certain BRAF gene mutations, including V600E and V600K, promote tumor growth.

The COLUMBUS trial showed that Mektovi plus Braftovi delayed progression of melanoma in people with BRAF V600 mutations more than Zelboraf (vemurafenib) and doubled progression-free survival. Mektovi was first approved in 2018.


Dosing Info:

Mektovi is a twice-daily tablet that can be taken with or without food.

Side Effects

Common adverse reactions of Mektovi plus Braftovi include fatigue, nausea, vomiting, diarrhea and abdominal pain. More serious adverse events may include heart problems, blood clots, eye problems, lung disease, liver toxicity, muscle damage and bleeding. Mektovi can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: August 9, 2020